



ASX Announcement

COMPANY UPDATE

**MEDLAB CLINICAL LTD
A.C.N. 169 149 071
("Medlab" or "THE COMPANY")**

Sydney, June 07, 2023 – Medlab Clinical Ltd (ASX:MDC) ("Medlab" or "the Company") is releasing the following update to stakeholders.

Dear Shareholder,

Our prior announcement estimated an update to the market would be possible by the end of May 2023. We thank shareholders for their patience as the Board and Hall Chadwick continue to address significant interest in the Medlab assets.

The international marketing campaign is identifying a range of interested parties, with due diligence and negotiations ongoing with various parties. As at the date of this announcement, the Company anticipates a substantive update may be provided in July 2023.

The Board confirms that operating costs have been significantly reduced, with a small team of part-time employees assisting with pivoting the Company's strategic direction. The Board, remaining staff, and Hall Chadwick are diligently working together on marketing the company, progressing discussions, and additional announcements will be made when appropriate milestones are met.

ENDS

Medlab requests that shareholders nominate a contact email address to streamline provision of further information. Please provide the shareholders' name, holder identification number ("HIN") or securityholder reference number ("SRN"), and the desired email address to medlabshareholders@hallchadwick.com.au

Should you have any queries, please do not hesitate to contact our office at medlabshareholders@hallchadwick.com.au